Functional Data
(Binding curve of anti-Cov-19&SARS S glycoprotein antibody IgG CR3022 to the trimeric Spike P.1, Gamma variant.)
COVID 19 Spike protein, P.1. variant of concern Coronavirus Recombinant Protein | COVID-19 recombinant protein
Recombinant SARS-CoV-2 Spike protein, P.1. variant of concern (Brazilian variant, L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I and V1176F)
Applications
IA (Immunoassay)
Purity
Affinity chromatography, >90% as estimated by SDS-PAGE
Synonyms
COVID 19 Spike protein, P.1. variant of concern Coronavirus; N/A; Recombinant SARS-CoV-2 Spike protein, P.1. variant of concern (Brazilian variant, L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I and V1176F); 2019 Novel Coronavirus; Coronavirus; CoV; COVID-19 virus; HCoV-2; Human Coronavirus 2019; SARS2; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; P.1 Variant of Concern; Brazil mutant; Brazilian variant; L18F; T20N; P26S; D138Y; R190S; K417T; E484K; N501Y; D614G; H655Y; T1027I; V1176F; Gamma Spike glycoprotein, Gamma variant of concern, Gamma mutant S protein. ; COVID-19 recombinant protein
Host
HEK293 Cells
Purity/Purification
Affinity chromatography, >90% as estimated by SDS-PAGE
Form/Format
Liquid; PBS 20% Glycerol
Sequence Positions
16-1211
Sequence
VNFTNRTQLPSAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNYPFLGYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLSEFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADFVIRGDEVRQIAPGQTGTIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEVNNSYECDIPIGAGICASYQTQTNSPRGAGSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSPIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGPALQIPFPMQMAYRFNGIGTQNVLYENQKLIANQFNSAIGKIQDSLSSTPSALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDPPEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAAIKMSECVLGQSKVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLDISGINASFVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKGSGSGYIPEAPRDGQAYVRKDGEWVLLSTFLGSGHHHHHHHH
Applicable Applications for COVID-19 recombinant protein
IA (Immunoassay)
Species
Severe Acute Respiratory Syndrome Coronavirus 2
Amount Sent
0.2 ml of 0.62 mg/ml by A280 absorbance=120 ug (lot specific)
Tag
8xHis at the C terminus.
Endotoxin
Less than 0.1 ng/ug (1 IEU/ug), as measured by LAL method.
Dry Ice Shipment
Extra charge fee may add to your shipping cost as dry ice is required to ship this product.
Preparation and Storage
The protein can be stored at 2-8°C for 1 month. For long term, it should be stored at -20°C to -70°C preferably in small aliquots to avoid repeated freeze-thaw cycles.
Functional Data
(Binding curve of anti-Cov-19&SARS S glycoprotein antibody IgG CR3022 to the trimeric Spike P.1, Gamma variant.)
Functional Data
(Binding curve of anti-Cov-19&SARS S glycoprotein antibody IgG CR3022 to the trimeric Spike P.1, Gamma variant.)
SDS-PAGE
(>90% as estimated by SDS-PAGE stained with Instant Blue Stain (Expedeon).)
SDS-PAGE
(>90% as estimated by SDS-PAGE stained with Instant Blue Stain (Expedeon).)
Related Product Information for COVID-19 recombinant protein
Full-length soluble with foldon trimerization motif, mutated Furin recognition site and 6 stabilising mutations (F817P, A892P, A899P, A942P, K986P and V987P), based on/modified from Amanat et al, 2020 and Hsieh et al, 2020.
The first reports of atypical pneumonia in China were announced at the very end of 2019, in the city of Wuhan, Hubei province. Its cause was identified in January 2020 as a novel β-CoV (1), named SARS-CoV-2, which started spreading very quickly causing a global pandemic COVID-19. Spike protein attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. Binding to human ACE2 receptor and internalization of the virus into the endosomes of the host cell induces conformational changes in the Spike glycoprotein (2, 3). The protein forms a trimer in vivo mediating receptor binding and membrane fusion (4). It has been demonstrated by Florian Krammer’s group that certain mutations and the inclusion of trimerization motif can stabilize recombinant Spike protein (5, 6). The original Wuhan strain of the virus has become quickly replaced by its more transmissible variant, mainly determined by a single amino acid point mutation D614G (7). A novel SARS-CoV-2 variant, P.1, known as Brazilian variant, originated in the Amazonas state of Brazil and started spreading quickly in adjacent countries as well as the USA (8,9).
The first reports of atypical pneumonia in China were announced at the very end of 2019, in the city of Wuhan, Hubei province. Its cause was identified in January 2020 as a novel β-CoV (1), named SARS-CoV-2, which started spreading very quickly causing a global pandemic COVID-19. Spike protein attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. Binding to human ACE2 receptor and internalization of the virus into the endosomes of the host cell induces conformational changes in the Spike glycoprotein (2, 3). The protein forms a trimer in vivo mediating receptor binding and membrane fusion (4). It has been demonstrated by Florian Krammer’s group that certain mutations and the inclusion of trimerization motif can stabilize recombinant Spike protein (5, 6). The original Wuhan strain of the virus has become quickly replaced by its more transmissible variant, mainly determined by a single amino acid point mutation D614G (7). A novel SARS-CoV-2 variant, P.1, known as Brazilian variant, originated in the Amazonas state of Brazil and started spreading quickly in adjacent countries as well as the USA (8,9).
References
1. Zhu N., Zhang D., Wang W., et al. China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med., 2020;382:727–733.
2. Hoffmann M., Kleine-Weber H., Schroeder S., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020;181(2):271-280.
3. Wrapp D., Wang N., Corbett KS., et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020;367(6483):1260-1263.
4. Yin HS., Wen X., Paterson RG., Lamb RA., Jardetzky TS. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature, 2006;439(7072):38-44.
5. Amanat, F., Stadlbauer, D., Strohmeier, S., et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med., 2020;26:1033–1036.
6. Stadlbauer, D., Amanat, F., Chromikova, V., et al. SARS?CoV?2 seroconversion in humans: A detailed protocol for a serological assay, antigen production, and test setup. Current Protocols in Microbiology, 2020;57, e100.
7. Korber, B., Fischer, W., Gnanakaran, S., et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell, 2020;182:1-16.
8. Tegally, H., Wilkinson, E., Giovanetti, M., et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple Spike mutations in South Africa. MedRxiv, 21.12.2020;182:1-16.
2. Hoffmann M., Kleine-Weber H., Schroeder S., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell, 2020;181(2):271-280.
3. Wrapp D., Wang N., Corbett KS., et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 2020;367(6483):1260-1263.
4. Yin HS., Wen X., Paterson RG., Lamb RA., Jardetzky TS. Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation. Nature, 2006;439(7072):38-44.
5. Amanat, F., Stadlbauer, D., Strohmeier, S., et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med., 2020;26:1033–1036.
6. Stadlbauer, D., Amanat, F., Chromikova, V., et al. SARS?CoV?2 seroconversion in humans: A detailed protocol for a serological assay, antigen production, and test setup. Current Protocols in Microbiology, 2020;57, e100.
7. Korber, B., Fischer, W., Gnanakaran, S., et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell, 2020;182:1-16.
8. Tegally, H., Wilkinson, E., Giovanetti, M., et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple Spike mutations in South Africa. MedRxiv, 21.12.2020;182:1-16.
NCBI and Uniprot Product Information
UniProt Accession #
Molecular Weight
Predicted Molecular Weight: 137 kDa
Estimated Molecular Weight, SDS-PAGE: ≈190 kDa
Estimated Molecular Weight, SDS-PAGE: ≈190 kDa
Similar Products
Product Notes
The COVID-19 (Catalog #AAA47145) is a Recombinant Protein produced from HEK293 Cells and is intended for research purposes only. The product is available for immediate purchase. The immunogen sequence is 16-1211. AAA Biotech's COVID 19 Spike protein, P.1. variant of concern Coronavirus can be used in a range of immunoassay formats including, but not limited to, IA (Immunoassay). Researchers should empirically determine the suitability of the COVID-19 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. The amino acid sequence is listed below: VNFTNRTQLP SAYTNSFTRG VYYPDKVFRS SVLHSTQDLF LPFFSNVTWF HAIHVSGTNG TKRFDNPVLP FNDGVYFAST EKSNIIRGWI FGTTLDSKTQ SLLIVNNATN VVIKVCEFQF CNYPFLGYYH KNNKSWMESE FRVYSSANNC TFEYVSQPFL MDLEGKQGNF KNLSEFVFKN IDGYFKIYSK HTPINLVRDL PQGFSALEPL VDLPIGINIT RFQTLLALHR SYLTPGDSSS GWTAGAAAYY VGYLPRTFLL KYNENGTITD AVDCALDPLS ETKCTLKSFT VEKGIYQTSN FRVQPTESIV RFPNITNLCP FGEVFNATRF ASVYAWNRKR ISNCVADYSV LYNSASFSTF KCYGVSPTKL NDLCFTNVYA DFVIRGDEVR QIAPGQTGTI ADYNYKLPDD FTGCVIAWNS NNLDSKVGGN YNYLYRLFRK SNLKPFERDI STEIYQAGST PCNGVKGFNC YFPLQSYGFQ PTYGVGYQPY RVVVLSFELL HAPATVCGKK STNLVKNKCV NFNFNGLTGT GVLTESNKKF LPFQQFGRDI ADTTDAVRDP QTLEILDITP CSFGGVSVIT PGTNTSNQVA VLYQGVNCTE VPVAIHADQL TPTWRVYSTG SNVFQTRAGC LIGAEVNNSY ECDIPIGAGI CASYQTQTNS PRGAGSVASQ SIIAYTMSLG AENSVAYSNN SIAIPTNFTI SVTTEILPVS MTKTSVDCTM YICGDSTECS NLLLQYGSFC TQLNRALTGI AVEQDKNTQE VFQVKQIYKT PPIKDFGGFN FSQILPDPSK PSKRSPIEDL LFNKVTLADA GFIKQYGDCL GDIAARDLIC AQKFNGLTVL PPLLTDEMIA QYTSALLAGT ITSGWTFGAG PALQIPFPMQ MAYRFNGIGT QNVLYENQKL IANQFNSAIG KIQDSLSSTP SALGKLQDVV NQNAQALNTL VKQLSSNFGA ISSVLNDILS RLDPPEAEVQ IDRLITGRLQ SLQTYVTQQL IRAAEIRASA NLAAIKMSEC VLGQSKVDFC GKGYHLMSFP QSAPHGVVFL HVTYVPAQEK NFTTAPAICH DGKAHFPREG VFVSNGTHWF VTQRNFYEPQ IITTDNTFVS GNCDVVIGIV NNTVYDPLQP ELDSFKEELD KYFKNHTSPD VDLDISGINA SFVNIQKEID RLNEVAKNLN ESLIDLQELG KYEQYIKGSG SGYIPEAPRD GQAYVRKDGE WVLLSTFLGS GHHHHHHHH. It is sometimes possible for the material contained within the vial of "COVID 19 Spike protein, P.1. variant of concern Coronavirus, Recombinant Protein" to become dispersed throughout the inside of the vial, particularly around the seal of said vial, during shipment and storage. We always suggest centrifuging these vials to consolidate all of the liquid away from the lid and to the bottom of the vial prior to opening. Please be advised that certain products may require dry ice for shipping and that, if this is the case, an additional dry ice fee may also be required.Precautions
All products in the AAA Biotech catalog are strictly for research-use only, and are absolutely not suitable for use in any sort of medical, therapeutic, prophylactic, in-vivo, or diagnostic capacity. By purchasing a product from AAA Biotech, you are explicitly certifying that said products will be properly tested and used in line with industry standard. AAA Biotech and its authorized distribution partners reserve the right to refuse to fulfill any order if we have any indication that a purchaser may be intending to use a product outside of our accepted criteria.Disclaimer
Though we do strive to guarantee the information represented in this datasheet, AAA Biotech cannot be held responsible for any oversights or imprecisions. AAA Biotech reserves the right to adjust any aspect of this datasheet at any time and without notice. It is the responsibility of the customer to inform AAA Biotech of any product performance issues observed or experienced within 30 days of receipt of said product. To see additional details on this or any of our other policies, please see our Terms & Conditions page.Item has been added to Shopping Cart
If you are ready to order, navigate to Shopping Cart and get ready to checkout.